- Published at
- by financialpost.com
positive
positive
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“
News for Psyence Group Inc. (PSYG.CN)
- Published at
- by manilatimes.net
positivepositive- Published at
- by globenewswire.com
positivepositivePsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disord
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin...- Published at
- by manilatimes.net
positivepositive- Published at
- by financialpost.com
positivepositivePsyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“- Published at
- by investing.com
positivepositivePsyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones By Investing.com
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones- Published at
- by financialpost.com
positivepositivePsyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care- Published at
- by financialpost.com
positivepositivePsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adj
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“- Published at
- by financialpost.com
positivepositivePsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“- Published at
- by financialpost.com
positivepositivePsyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“- Published at
- by investing.com
positivepositivePsyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business By Investing.com
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business- Published at
- by financialpost.com
positivepositivePsyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
TORONTO, March 26, 2024 (GLOBE NEWSWIRE) — Further to the announcement by Psyence Group Inc (“